Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis

NCT ID: NCT05182034

Last Updated: 2025-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 94 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-24
• Study Completion Date: 2023-10-17

Brief Summary

This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee - i.e., the more severely affected knee), and enroll in this study.

Detailed Description

Patients who meet the inclusion/exclusion criteria will be randomly assigned at visit 2 to either of study group 1(low-dose), study group 2 (mid-dose) or active control group at 1:1:1 ratio. Patients will be administered with investigational product. Investigational product will be administered into the to-be-treated (index) knee one time within 7 days after randomization.

All patients enrolled will be followed up a total of 6 times (1, 4, 8, 12, 24, and 52 weeks) for up to post-dose 12 months. The patients should visit the study facility according to the visit schedule, and will undergo safety evaluation (vital sign, laboratory test, etc.) and efficacy evaluation [Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 100-mm visual analogue scale (VAS), International Knee Documentation Committee (IKDC) subjective knee evaluation].

Conditions

Knee Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Study Group 1: SMUP-IA-01 (low dose)

Investigational Product - 4.0×10\^6 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

Group Type: EXPERIMENTAL

SMUP-IA-01(low dose)

Intervention Type: BIOLOGICAL

A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

Study Group 2:SMUP-IA-01 (mid dose)

Investigational Product - 1.0×10\^7 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

Group Type: EXPERIMENTAL

SMUP-IA-01(mid dose)

Intervention Type: BIOLOGICAL

A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

Active Control Group

Investigational Product - 2 ml of 1% sodium hyaluronate (2 ml of sodium chloride injection is administered before administration of 1% sodium hyaluronate)

Group Type: ACTIVE_COMPARATOR

Active Control Group Sodium chloride

Intervention Type: DRUG

A single knee administration of Sodium chloride

Interventions

SMUP-IA-01(low dose)

A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

Intervention Type: BIOLOGICAL

SMUP-IA-01(mid dose)

A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

Intervention Type: BIOLOGICAL

Active Control Group Sodium chloride

A single knee administration of Sodium chloride

Intervention Type: DRUG

Other Intervention Names

SMUP allogenic cord blood-derived mesenchymal stem cell (SMUP-Cell); SMUP allogenic cord blood-derived mesenchymal stem cell (SMUP-Cell); Sodium chloride

Eligibility Criteria

Inclusion Criteria

1. Patients who are ≥ 19 years of age on the date on which the consent form was signed

2. Patients diagnosed with knee osteoarthritis in at least one knee according to the clinical and radiological definition criteria of American College of Rheumatology (ACR) guidline at screening visit

3. Patients with knee OA corresponding to K&L Grade 2 or 3 on radiographic examination at screening visit

4. Patients with less than 35 of BMI at screening visit

5. Patients who voluntarily decide to participate and sign the consent form

6. Patients who have persistent symptoms despite having undergone a reasonable trial of standard therapy (i.e., for a minimum of 3 months)

Exclusion Criteria

1. Patients with any of the following diseases.

• infectious arthritis, autoimmune or inflammatory joint diseases, gout, recurrent pseudogout, Paget's disease, intra-articular displaced fracture, ochronosis, acromegaly, haemochromatosis, Wilson's disease, genetic disease (hyperkinesia etc.), genetic collagen disorder, etc.

2. Patients who have ever undergone surgery or radiotherapy in the knee joint area within the 12 weeks prior to the screening visit date, or who have not been recovered from its side effect yet.

3. Patients with SIF (Subchondral insufficiency fracture) corresponding to type II of the RPOA (rapidly progressive osteoarthritis).

4. Patients whose physical examination results show severe degree of ligament instability.

5. Patients who have ever been given any intraarticular drug injection (i.e., hyaluronic acid injection, etc.) in to-be-treated (index) knee within the 6 months, prior to the screening visit date.

6. Patients who have ever been given steroids via intraarticular injection in to-be-treated (index) knee within the 12 weeks prior to the screening visit date.

7. Patients who have ever taken medications or given therapy below within the past 2 weeks on the basis of screening visit date. However, if patients have 14 days of wash-out period, the patient is allowed to participate.

• drugs containing the ingredient of glucosamine, chondroitin sulfate, or diacerein
• drugs containing herbal ingredient or herbal drugs for knee OA pain relief
• anti-inflammatory analgesics or NSAIDs (prescription/non-prescription drugs). (However, patients who take acetaminophen and have 3 days of wash-out period are allowed to participate.)
• oral steroids
• hospital physiotherpy or oriental medicine treatment (buhang, acupunture, moxibustion etc.)

8. Patients who have skin disease on injection site or who are judged inappropriate for intra-articular injection on to-be-treated knee.

9. Patients who are judged unsuitable for MRI scanning (3.0 Tesla or higher) due to an insertion of metal material (i.e., heart pacemaker, cerebral aneurysm clip, etc.) or obstructive phobia. However, patients who have an insertion of metal material that is not affected by the magnetic field is allowed to participate

10. Patients with clinically significant past or present illness as follows;

• heart diseases (i.e., myocardial infarction, coronary artery bypass surgery, arrhythmia and other serious heart diseases, etc.)
• uncontrolled hypertension (not controlled down to 140/90 mmHg or below even after treatment with 3 or more antihypertensive drugs)
• kidney disease (i.e., chronic kidney failure, glomerulonephritis, etc.)
• liver disease (i.e., acute or chronic liver disease such as cirrhosis, fatty liver, etc.)
• endocrine diseases (i.e., thyroiditis, diabetes insipidus, Cushing's disease, etc.)
• other serious systemic diseases

11. Patient with ongoing autoimmune disorder that requires treatment with an immunosuppressive medication

12. Patients with infection that requires administration of parenteral antibiotics

13. Patients with a history of mental illness or epilepsy

14. Patients who have been diagnosed with cancer within the 5 years prior to the screening visit date

15. Patients who have been given immunosuppressive drugs such as cyclosporin A or azathioprine within the 6 weeks prior to the screening visit

16. Patients with a history of allergic reactions to hyaluronic acid injections, cryoprotectant (dimethyl sulfoxide, DMSO), or gentamicin.

17. Patients who are pregnant or lactating, or patients who have a plan to become pregnant during the study period

18. Male or female patients who do not agree to avoid pregnancy or the use of appropriate contraceptive methods during the study period. But women who have given infertility surgery or who have passed menopause one year or more are allowed to participate without the consent for contraception.

19. Patients who have been given any other cell therapy products or who plan to do so during the study period.

20. Patients who have been given any other investigational products including device within the 3 months prior to the screening visit date.

21. Patients who are judged by the investigator as inappropriate for enrollment into the study, for any reasons other than the reasons specified above.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medipost Co Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Myungchul Lee, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Hospital

Chonghyuk Choi, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Severance Hospital

Chongbum Chang, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul Nation University Bundang Hospital

Seungbum Han, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Korea University Anam Hospital

Sunghwan Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Gangnam Severance Hospital

Locations

Seoul Nation University Bundang Hospital

Gyeonggi-do, , South Korea

Gangnam Severance Hospital

Seoul, , South Korea

Korea University Anam Hospita

Seoul, , South Korea

Seoul National University Hospital

Seoul, , South Korea

Severance Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

MP-SMUP-IA-01-P02

Identifier Type: -

Identifier Source: org_study_id